SUPPLEMENTARY TABLE. Evaluation of SARS-CoV-2 RNA Rebound Following Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

SUPPLEMENTARY TABLE. Evaluation of SARS-CoV-2 RNA Rebound Following Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022

12/22/2023
By Centers for Disease Control and Prevention (U.S.)
Series: MMWR. Morbidity and mortality weekly report

[PDF-200.40 KB]

English

Details Related Documents You May Also Like

Details:

Corporate Authors:

Centers for Disease Control and Prevention (U.S.)
Series:

MMWR. Morbidity and mortality weekly report
Document Type:

Journal Article
Place as Subject:

United States
Volume:

72
Issue:

51
Collection(s):

Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha256:67b78a1d5b79fe2a34b33cb41b37dac8a075302cfc66cd3563b9e731166c52d7
Download URL:

https://stacks.cdc.gov/view/cdc/136166/cdc_136166_DS1.pdf
File Type:

No Additional Files

More +

SUPPLEMENTARY TABLE. Evaluation of SARS-CoV-2 RNA Rebound Following Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022

Details:

Supporting Files

Related Documents

You May Also Like